Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.
Talis Biomedical, a US-based developer of molecular diagnostic tests for infectious diseases that was spun out of California Institute of Technology (Caltech), has priced its shares at $16 to raise more than $220m in its IPO.
The company issued 13.8 million shares and began trading on the Nasdaq Global Market on Friday, and shares surged nearly 74% on the first day of trading to close at $27.80. Talis is listed under the ticker symbol TLIS.
Founded in 2010, Talis Biomedical…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
